Amid a global rush to judgment among several regulatory authorities, pharmaceutical companies, chain drugstores and trial lawyers on the potential carcinogenicity of ranitidine, the US Food and Drug Administration remains a conspicuous holdout.
Now the agency is questioning the third-party test results obtained by an online pharmacy, Valisure LLC, that set the recalls in motion